Rachel joined Winslow Capital in 2023 as a Sector PM/Analyst focusing on researching the Healthcare sector for the U.S. Large Cap Growth Strategies. She utilizes her bioengineering background to analyze science-driven companies where understanding the enabling technology and a critical review of clinical trial data is required to come to an investment decision. Prior to joining, Rachel was a Vice President and Investment Analyst at T. Rowe Price covering public and private healthcare companies. She also served as a Medical Analyst at Sands Capital Management.
M.B.A. Harvard Business School, High Distinction, Baker Scholar
M.S.E. Bioengineering, University of Pennsylvania
B.S.E. Bioengineering, University of Pennsylvania, Cum Laude
B.S.E. Finance, University of Pennsylvania, The Wharton School, Cum Laude